KIT and chronic myelogenous leukemia, BCR-ABL1 positive: The possible profile of LSCs in CML could be Lin−CD34+CD38−CD45RA−/Low, CD117 (KIT)−, CD26+, and CD90+ that are identified as potential therapeutic targets at a single-cell level with a higher proliferative and colony-forming potential than normal HSCs [37, 48].